Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
On September 23, 2025, Seres Therapeutics, Inc. (the "Company") announced actions to reduce operating costs in order to...
Following recent constructive FDA feedback, Seres anticipates finalizing SER-155 Phase 2 study protocol for the prevention of b...
Seres Therapeutics (NASDAQ:MCRB) reported quarterly losses of $(2.27) per share which beat the analyst consensus estimate of $(...
